Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

0 patients from sites throughout Europe, South America, Asia Pacific and the Middle East.

About Non-Small Cell Lung Cancer (NSCLC)(1)

Non-small cell lung cancer accounts for 85-90% of diagnosed lung cancers and is a disease in which malignant (cancer) cells form in the tissues of the lung. It is characterized by several types of lung cancers, each of which grow and spread in different ways, including: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

Every year 1.4 million people worldwide will be diagnosed with lung cancer.  There are nearly 205,000 new cases in the United States and approximately 375,000 new cases in Europe each year.  Annual deaths as a result of non small cell lung cancer are estimated at 160,000 in the United States and 342,000 in Europe.

Nexavar's Differentiated Mechanism
Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigat
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Diseases largely eradicated in the ... Measles was declared eliminated in 2000, yet the CDC ... 15—the highest incidence in 20 years. In July, ... cough a problem of "epidemic proportions." ... from these preventable diseases—in part because some parents (more ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)...  In part four of a blog ... as a strategic asset, Mary Baxter, MBA, RPh ... Health,s Innovation Delivery Solutions business, discusses how expanding patient ... and patients. "Every hospital pharmacist knows that ... job in a value-based healthcare world," Baxter says. "For ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
(Date:8/30/2014)... (PRWEB) August 30, 2014 Insomnia causes disturbances ... listeners understand how they unknowingly developed insomnia and the steps ... nights during. Tune in to the show at this ... show airs live on August 30, and will be podcasted ... on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia causes ...
(Date:8/30/2014)... Springs, CO (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) rob people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... medication commonly used to treat gout, before and ... potential complications from this type of surgery, but ... effects, according to a study published by ... online to coincide with its presentation at the ... after cardiac surgery include postpericardiotomy syndrome (the occurrence ...
(Date:8/30/2014)... August 30, 2014 Serving contented clients ... India, Profit By Outsourcing is now offering discount ... The company gives emphasize on putting forward the best ... to clients. Their dedicated team of professionals and web ... They can handle even the critical issues of web ...
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 "I ... beach because of her crutches," said an inventor from Wetumpka, ... the sights and sounds of the shore, I came up ... beach sand." , She created a prototype for the patent-pending ... The accessory enables the individual to use crutches, walkers, or ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... Stock Exchange Symbol: CYT, MONTREAL, Oct. ... leader in cardiac arrhythmia products to treat ... Inc. a patent,infringement lawsuit in the United ... CryoCor makes and sells cryosurgical consoles, ...
... Oct. 16 Genzyme Corporation,(Nasdaq: GENZ ) ... Advisory Committee meeting, during which the committee voted ... the FDA extend the indications,for phosphate binders to ... Renagel(R) (sevelamer hydrochloride), the most,prescribed phosphate binder in ...
... Squirrel Hill Facility and Expand Programs ... ... Institute announced,the launch of the public phase of The Campaign for ... of pediatric,rehabilitation services in western Pennsylvania, The Children,s Institute,will use the ...
... ... IRVINE, Calif., Oct. 16 Edwards Lifesciences,Corporation ... products and technologies to,treat advanced cardiovascular disease, today ... Foundation,s (CRF) nineteenth,annual Transcatheter Cardiovascular Therapeutics (TCT) scientific,symposium, ...
... With both the Senate and,House expected to vote this ... Health Insurance Program (SCHIP) legislation, U.S.,Senator Sherrod Brown (D-OH) ... came together on a news conference call to urge ... The SCHIP legislation would provide $35 billion in ...
... to all approved drugs used to fight ear infections ... tomorrow in the Journal of the American Medical Association ... it is their standard practice to perform an uncommon ... antibiotics fail to clear up their ear infections. The ...
Cached Medicine News:Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 2Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 3Health News:The Children's Institute Launches The Campaign for an Amazing Future 2Health News:The Children's Institute Launches The Campaign for an Amazing Future 3Health News:Edwards Lifesciences Announces Schedule of Activities at TCT 2007 2Health News:Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3Health News:Edwards Lifesciences Announces Schedule of Activities at TCT 2007 4Health News:Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 2Health News:Ear infection superbug discovered to be resistant to all pediatric antibiotics 2Health News:Ear infection superbug discovered to be resistant to all pediatric antibiotics 3Health News:Ear infection superbug discovered to be resistant to all pediatric antibiotics 4
... The ABI Prism 7000 Sequence ... PCR system that detects and quantitates ... cycle-by-cycle detection of accumulated PCR product ... cycling, fluorescence detection, and application-specific software ...
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
Medicine Products: